The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSVΔG-ZEBOV-GP Vaccine Tolerability and Safety during the West Africa Ebola Outbreak
journal contribution
posted on 2021-06-16, 16:22authored byM Samai, JF Seward, ST Goldstein, BE Mahon, DR Lisk, MA Widdowson, MI Jalloh, SJ Schrag, A Idriss, RJ Carter, P Dawson, SAS Kargbo, B Leigh, M Bawoh, J Legardy-Williams, G Deen, W Carr, A Callis, R Lindblad, JBW Russell, CR Petrie, AE Fombah, B Kargbo, W McDonald, Olamide JarrettOlamide Jarrett, RE Walker, P Gargiullo, D Bash-Taqi, L Gibson, AB Fofanah, A Schuchat, K Neuzil, H Insip, G Risi, S Sow
The West Africa Ebola epidemic stimulated rapid implementation of Ebola vaccine trials in the 3 highly affected countries. In Sierra Leone, we studied the recombinant vesicular stomatitis virus Ebola vaccine (rVSVΔG-ZEBOV-GP) safety and efficacy. The Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) was a randomized, unblinded Phase 2/3 trial with phased vaccine introduction, no placebo, and concurrent evaluation of vaccine safety and efficacy. Healthcare and frontline response workers in 5 districts were randomized to immediate or deferred (18-24 weeks later) vaccination and followed for 6 months postvaccination. We enrolled 8651 participants from April through August 2015; 7998 were vaccinated. No participants developed Ebola virus disease so an efficacy assessment was not possible. Overall, 132 (1.5%) participants experienced serious adverse events (SAEs); none were vaccine-related. In a detailed safety substudy (N = 436), vaccinated participants reported significantly more systemic adverse events (AEs) within 7 days than unvaccinated participants including fever higher than 38°C (20.5% vs 3.9%), headache (71.2% vs 22.1%), fatigue (50.7% vs 10.4%), and joint pain (31.7% vs 6.5%); most AEs were mild to moderate severity and resolved within 5 days. During days 5-28, vaccinated participants more commonly reported joint pain (17.0% vs 4.8%) and rash (7.8% vs 1.7%) (P<.05 for both comparisons). Vaccinated participants also more commonly reported skin vesicles (2.0% vs 0%) and mouth ulcers (2.0% vs 0%) but only during days 8-14 (P<.05 for both comparisons). Among almost 8000 high-risk workers vaccinated during the Sierra Leone Ebola epidemic, rVSVΔG-ZEBOV-GP was generally well tolerated with no vaccine-related SAEs. Reported joint pain, rash, skin vesicles, and mouth ulcers postvaccination are consistent with conditions associated with transient viral replication described among participants in other trials.
History
Citation
Samai, M., Seward, J. F., Goldstein, S. T., Mahon, B. E., Lisk, D. R., Widdowson, M. A., Jalloh, M. I., Schrag, S. J., Idriss, A., Carter, R. J., Dawson, P., Kargbo, S. A. S., Leigh, B., Bawoh, M., Legardy-Williams, J., Deen, G., Carr, W., Callis, A., Lindblad, R.Sow, S. (2018). The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSVΔG-ZEBOV-GP Vaccine Tolerability and Safety during the West Africa Ebola Outbreak. Journal of Infectious Diseases, 217(suppl_1), S6-S15. https://doi.org/10.1093/infdis/jiy020